Results 111 to 120 of about 21,045 (251)

Optimizing the Multimerization Properties of Quinoline-Based Allosteric HIV-1 Integrase Inhibitors

Viruses
Allosteric HIV-1 Integrase (IN) Inhibitors or ALLINIs bind at the dimer interface of the IN, away from the enzymatic catalytic site, and disable viral replication by inducing over-multimerization of IN.
Jian Sun, Jacques J. Kessl
doaj   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Efavirenz's effects on cytochrome P450 2C9 (CYP2C9) activity have not been formally characterized in vivo. We conducted the first clinical drug–drug interaction (DDI) study to test the effect of chronic efavirenz dosing on CYP2C9 activity, using tolbutamide as a selective probe.
Jason D. Kim, Ingrid F. Metzger, Jessica Bo Li Lu, Todd C. Skaar, Zeruesenay Desta   +4 more
wiley   +1 more source

Human Immunodeficiency Virus Integrase Pharmacophore Model Derived from Diketoacids Inhibitors [PDF]

, 2009
Xiaoyi Zhang
openalex   +1 more source

Predictors of discontinuing injectable cabotegravir/rilpivirine and virologic outcomes after resuming oral antiretroviral therapy

HIV Medicine, Volume 27, Issue 2, Page 217-225, February 2026.
Abstract Objective Evaluate factors associated with discontinuation of long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). Methods This is a retrospective cohort study at a single‐centre primary care HIV clinic.
Tali Faggiano, Jeffrey Yin, Nimish Patel, Afsana Karim, Kari Abulhosn, Laura Bamford, Lucas Hill   +6 more
wiley   +1 more source

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, Volume 27, Issue 2, Page 186-199, February 2026.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

Temporal network analysis of comorbidities among people with HIV in South Carolina

HIV Medicine, Volume 27, Issue 2, Page 257-269, February 2026.
Abstract Introduction People with HIV experience a high rate of comorbidities that can complicate their health outcomes. Understanding the prevalence, interrelationships and temporal development of these comorbidities is crucial for improving health management and quality of life for people with HIV.
Yunqing Ma, Matthew Lohman, Monique J. Brown, Yichen Li, Xiaoming Li, Bankole Olatosi, Jiajia Zhang   +6 more
wiley   +1 more source

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir [PDF]

, 2018
Robert Ziegler, Bimbisar Desai, Jo‐Ann Jee, B. Frank Gupton, Thomas D. Roper, Timothy F. Jamison   +5 more
openalex   +1 more source

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada

, 2018
Hezhao Ji, Aileen P. Patterson, Tracy Taylor, Claudia Rank, Jessica Halverson, Rupert Capiña, James Brooks, Paul Sandstrom   +7 more
openalex   +1 more source

CoMFA and CoMSIA Studies on Inhibitors of HIV‐1 Integrase ‐ Bicyclic Pyrimidinones [PDF]

, 2010
V. Radhika, Sivan Sree Kanth, Vijjulatha Manga   +2 more
openalex   +1 more source

Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men [PDF]

, 2022
Richard E. Haaland, Jeffrey J. Fountain, Amy Martin, Chuong Dinh, Angela Holder, Tiancheng Edwards, L. Davis Lupo, LaShonda Hall, Christopher Conway-Washington, Ivana Massud, J. Gerardo Garcı́a-Lerma, Colleen F. Kelley, Walid Heneine   +12 more
openalex   +1 more source